Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a confirmed type of advanced (Stage IV) non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
• People who are able to provide a stored tumour tissue sample, or who can have a fresh tumour biopsy taken if no stored sample is available and it is safe to do so.
• People who have at least one tumour that can be measured on a scan, where the longest dimension is 10mm or more.
• People who, in the opinion of the trial doctor, have a life expectancy of at least 12 weeks.
• People whose organs (such as kidneys, liver, and bone marrow) are functioning well enough to meet the trial's requirements.
• People who are willing to use contraception in line with local guidelines for clinical trial participants.

Additional requirements for one part of the trial (Sub Study 2):

• People whose tumour tests show a PD-L1 score of 1% or higher (based on local laboratory results).
• People whose blood clotting and urine tests meet the trial's requirements.
• People who weigh at least 30 kg.

Who may not be able to join:

• People whose lung cancer has a specific genetic change (such as EGFR mutations or ALK fusions) for which an approved targeted treatment already exists as a standard first-line option locally.
• People whose lung cancer includes small cell or neuroendocrine components.
• People who have severe or uncontrolled health conditions, including uncontrolled high blood pressure, active bleeding, active infection, lung inflammation, unstable blood clots in the veins, serious ongoing bowel conditions, active non-infectious skin disease, or substance misuse issues.
• People who have previously had a stem cell, bone marrow, donor tissue, or solid organ transplant.
• People who have an active autoimmune disease that has required ongoing treatment with systemic medications at any point in the past 5 years.
• People who have a history of a clinically significant heart rhythm problem, heart muscle disease of any cause, or heart failure with symptoms.
• People who have had another cancer in the past, unless it was fully treated with the aim of cure and has shown no signs of returning for at least 2 years before joining the trial.
• People who still have side effects rated Grade 2 or higher from previous cancer treatments (hair loss is an exception).
• People who have spinal cord compression or brain metastases that are causing symptoms.
• People who are currently receiving other cancer treatments or medications that suppress the immune system.
• People who have had radiation therapy to a limited area within the past 2 weeks, or to a large area (or more than 30% of the bone marrow) within the past 4 weeks.

Additional exclusions for one part of the trial (Sub Study 2):

• People with a known active hepatitis A infection.
• People with an active hepatitis B infection, or a chronic hepatitis B infection with a high level of the virus in the blood.
• People with an active hepatitis C infection, or a hepatitis C infection that has only been cleared for less than 12 weeks following treatment.
• People with HIV that is not well managed.
• People who show signs of bleeding in the brain (Grade 1 or higher on clinical rating scales).
• People with uncontrolled high blood pressure of 150 mmHg or higher (top number) and/or 100 mmHg or higher (bottom number).
• People whose cancer is shown on scans to be invading or surrounding major blood vessels, invading major airways, or where there are hollow spaces within the tumour.
• People who have previously had a serious arterial blood clot, a severe bleeding event (Grade 3 or higher), or significant coughing up of blood.
• People who have significant bleeding disorders, a wound or ulcer that is not healing, or clinically relevant heart failure.
• People who have a bowel obstruction, inflammatory bowel disease, or have had a large portion of the bowel removed.
• People who have liver cirrhosis rated at Child-Pugh B or worse, or any degree of cirrhosis combined with a history of liver-related confusion (hepatic encephalopathy) or significant fluid build-up in the abdomen from cirrhosis.
• People who have previously received systemic treatment for advanced or metastatic NSCLC.
• People who have previously been treated with certain immunotherapy drugs, including anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-TIGIT therapies, or similar immune-targeting treatments.
• People who regularly take blood-thinning medications that work against platelets.
• People who have previously received anti-VEGF therapy (a type of treatment that targets blood vessel growth).
• People for whom the chemotherapy combinations or the drug ramucirumab specified in this trial are medically unsuitable.
• People with a known allergy or hypersensitivity to any of the drugs used in this trial, including rilvegostomig, cisplatin, carboplatin, paclitaxel, nab-paclitaxel, pemetrexed, or ramucirumab, or to any of their ingredients.

Important: Always verify eligibility with the trial site directly before applying.